18F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer

[1]  Brittany Z Dashevsky,et al.  Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma , 2015, The Journal of Nuclear Medicine.

[2]  Steven J. M. Jones,et al.  Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer , 2015, Cell.

[3]  D. Groheux,et al.  Breast Cancer Staging: To Which Women Should 18F-FDG PET/CT Be Offered? , 2015, The Journal of Nuclear Medicine.

[4]  Brittany Z Dashevsky,et al.  Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  Benjamin O. Anderson,et al.  Breast cancer version 2.2015: Clinical practice guidelines in oncology , 2015 .

[6]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. , 2015, The New England journal of medicine.

[7]  M. Gonen,et al.  Retrospective Analysis of 18F-FDG PET/CT for Staging Asymptomatic Breast Cancer Patients Younger Than 40 Years , 2014, The Journal of Nuclear Medicine.

[8]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[9]  E. Winer,et al.  Abstract P2-18-09: TBCRC 013: A prospective analysis of the role of surgery in stage IV breast cancer , 2013 .

[10]  P. Morris,et al.  Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. , 2013, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[11]  R. Sebro,et al.  Frequency and clinical implications of incidental new primary cancers detected on true whole-body 18F-FDG PET/CT studies , 2013, Nuclear medicine communications.

[12]  G. Paganelli,et al.  Preoperative PET/CT in early-stage breast cancer: is the TNM classification enough? , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Bernsdorf.  Reply to 'preoperative PET/CT in early-stage breast cancer: is the TNM classification enough?'. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  D. Groheux,et al.  Performance of FDG PET/CT in the clinical management of breast cancer. , 2013, Radiology.

[15]  D. Groheux,et al.  Prognostic Impact of 18FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer , 2012, Journal of the National Cancer Institute.

[16]  E. Winer,et al.  Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network , 2012, Cancer.

[17]  G. Hortobagyi,et al.  FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer. , 2011, The oncologist.

[18]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  M. A. Chung,et al.  Elevated Breast Cancer Mortality in Women Younger than Age 40 Years Compared with Older Women Is Attributed to Poorer Survival in Early-Stage Disease , 2009 .

[20]  J. Ross,et al.  The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. , 2009, The oncologist.

[21]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[22]  B. Cooper,et al.  Detection of clinically unexpected malignant and premalignant tumors with whole-body FDG PET: histopathologic comparison. , 2004, Radiology.

[23]  A. Cavaliere,et al.  Breast cancer in young women: clinicopathological features and biological specificity. , 2003, Breast.

[24]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[26]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[27]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[28]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[29]  Andres Forero,et al.  Breast Cancer Version 2.2015. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[30]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[31]  J. Thigpen.  Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer , 2011 .

[32]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.